JP6346904B2 - ベータ−ラクタマーゼ阻害剤 - Google Patents

ベータ−ラクタマーゼ阻害剤 Download PDF

Info

Publication number
JP6346904B2
JP6346904B2 JP2015552833A JP2015552833A JP6346904B2 JP 6346904 B2 JP6346904 B2 JP 6346904B2 JP 2015552833 A JP2015552833 A JP 2015552833A JP 2015552833 A JP2015552833 A JP 2015552833A JP 6346904 B2 JP6346904 B2 JP 6346904B2
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
acid
alkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015552833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506419A (ja
JP2016506419A5 (enExample
Inventor
バーンズ，クリストファー，ジェイ．
デイグル，デニス
リウ，ビン
マクギャリー，ダニエル
シー． ペビアー，ダニエル
シー． ペビアー，ダニエル
イー．リー トラウト，ロバート
イー．リー トラウト，ロバート
ジャクソン，ランディー，ダブリュー．
Original Assignee
ベナトルクス ファーマシューティカルズ，インク．
ベナトルクス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベナトルクス ファーマシューティカルズ，インク．, ベナトルクス ファーマシューティカルズ，インク． filed Critical ベナトルクス ファーマシューティカルズ，インク．
Publication of JP2016506419A publication Critical patent/JP2016506419A/ja
Publication of JP2016506419A5 publication Critical patent/JP2016506419A5/ja
Application granted granted Critical
Publication of JP6346904B2 publication Critical patent/JP6346904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015552833A 2013-01-10 2014-01-10 ベータ−ラクタマーゼ阻害剤 Expired - Fee Related JP6346904B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751161P 2013-01-10 2013-01-10
US61/751,161 2013-01-10
US201361783261P 2013-03-14 2013-03-14
US61/783,261 2013-03-14
PCT/US2014/011144 WO2014110442A1 (en) 2013-01-10 2014-01-10 Beta-lactamase inhibitors

Publications (3)

Publication Number Publication Date
JP2016506419A JP2016506419A (ja) 2016-03-03
JP2016506419A5 JP2016506419A5 (enExample) 2017-01-05
JP6346904B2 true JP6346904B2 (ja) 2018-06-20

Family

ID=51061422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552833A Expired - Fee Related JP6346904B2 (ja) 2013-01-10 2014-01-10 ベータ−ラクタマーゼ阻害剤

Country Status (6)

Country Link
US (6) US9403850B2 (enExample)
EP (1) EP2943204B1 (enExample)
JP (1) JP6346904B2 (enExample)
CN (1) CN105101970B (enExample)
ES (1) ES2730013T3 (enExample)
WO (1) WO2014110442A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518991A (ja) * 2014-06-11 2017-07-13 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9422314B2 (en) * 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008628A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9403850B2 (en) * 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
EP3140310B1 (en) 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
CA2947041A1 (en) * 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
LT6177B (lt) 2014-10-10 2015-07-27 Uab "Biocentras" Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
US10214501B2 (en) 2015-02-02 2019-02-26 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
WO2017100537A1 (en) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
NZ779170A (en) 2016-09-14 2025-08-29 Univ Nat Taiwan Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
WO2018134127A1 (en) 2017-01-23 2018-07-26 Basf Se Fungicidal pyridine compounds
EP3592362B1 (en) 2017-03-06 2025-02-19 Venatorx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
TW201841642A (zh) * 2017-04-28 2018-12-01 日商大日本住友製藥股份有限公司 雜環衍生物
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
CN107607572B (zh) * 2017-09-15 2019-12-03 山东大学齐鲁医院 一种用于离体细胞水溶性代谢物的二维核磁共振检测方法
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof
WO2019145177A1 (en) 2018-01-23 2019-08-01 Basf Se Bromination of pyridine derivatives
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
UA129150C2 (uk) * 2018-04-27 2025-01-29 Сумітомо Фарма Ко., Лтд. Оксозаміщена сполука
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CA3121130A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
MX2022004912A (es) 2019-10-25 2022-08-25 Sumitomo Pharma Co Ltd Novedoso compuesto de anillo condensado sustituido.
EP4065587A4 (en) * 2019-11-26 2023-12-27 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
CN111254091B (zh) * 2020-01-20 2022-04-19 浙江工业大学 一种嗜麦芽窄食单胞菌gyh及其在降解氯代烃类污染物中的应用
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
MX2022007854A (es) * 2021-06-23 2022-12-26 Yoda Pharmaceuticals Inc Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3.
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
DK1212327T3 (da) 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
EP1635812A2 (en) 2003-06-10 2006-03-22 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
ATE521612T1 (de) 2004-03-30 2011-09-15 Millennium Pharm Inc Synthese von boronsäureester- und boronsäureverbindungen
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
DK2484680T3 (da) * 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
MX2010005250A (es) 2007-11-13 2010-11-05 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa.
RS53862B1 (sr) 2008-01-18 2015-08-31 Merck Sharp & Dohme Corp. Inhibitori beta-laktamaze
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
KR20130031233A (ko) 2009-07-28 2013-03-28 아나코르 파마슈티칼스 인코포레이티드 삼치환된 붕소 함유 분자
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
BR112013032770A2 (pt) 2011-07-26 2017-02-07 Wockhardt Ltd composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
JP6129203B2 (ja) 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
ES2615744T3 (es) 2012-12-03 2017-06-08 F. Hoffmann-La Roche Ag Compuestos de ácido triazol-borónico sustituidos
US9422314B2 (en) 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9101638B2 (en) * 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008628A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9403850B2 (en) * 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
CA2947041A1 (en) * 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2950917C (en) 2014-06-11 2022-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US10206937B2 (en) * 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
EP3592362B1 (en) 2017-03-06 2025-02-19 Venatorx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3802538A4 (en) 2018-05-30 2022-01-12 Venatorx Pharmaceuticals, Inc. BROAD-SPECTRUM CARBAPENEMS
GB2583614B (en) 2018-06-11 2023-05-24 Venatorx Pharmaceuticals Inc Hepatitis B capsid assembly modulators
CN113015532B (zh) 2018-09-12 2024-03-15 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物
CA3121130A1 (en) 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
JP2022529212A (ja) 2019-04-02 2022-06-20 ベナトルクス ファーマシューティカルズ，インク． 経口送達されるベータ－ラクタマーゼ阻害剤の固体形態およびその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518991A (ja) * 2014-06-11 2017-07-13 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Also Published As

Publication number Publication date
US9771382B2 (en) 2017-09-26
EP2943204A4 (en) 2016-11-09
HK1217446A1 (zh) 2017-01-13
US9403850B2 (en) 2016-08-02
ES2730013T3 (es) 2019-11-07
EP2943204A1 (en) 2015-11-18
CN105101970B (zh) 2018-11-20
US20160016978A1 (en) 2016-01-21
WO2014110442A1 (en) 2014-07-17
US20170342093A1 (en) 2017-11-30
US20140194386A1 (en) 2014-07-10
US20160304539A1 (en) 2016-10-20
US11414435B2 (en) 2022-08-16
JP2016506419A (ja) 2016-03-03
US10125152B2 (en) 2018-11-13
US9376454B2 (en) 2016-06-28
US9040504B2 (en) 2015-05-26
EP2943204B1 (en) 2019-03-13
US20200317698A1 (en) 2020-10-08
US20150224125A1 (en) 2015-08-13
CN105101970A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
JP6346904B2 (ja) ベータ−ラクタマーゼ阻害剤
JP6403219B2 (ja) ベータ−ラクタマーゼ阻害剤
US10294248B2 (en) Beta-lactamase inhibitors
EP3347008B1 (en) Beta-lactamase inhibitors
US20170145037A1 (en) Orally bioavailable beta-lactamase inhibitors
HK1217446B (zh) β-内酰胺酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180528

R150 Certificate of patent or registration of utility model

Ref document number: 6346904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees